Dieser Anti-BRCC3 Antikörper ist ein Kaninchen Polyklonal Antikörper zur Detektion von BRCC3 in WB, ELISA, IHC (p) und IF. Geeignet für Human, Maus und Ratte.
Produktnummer ABIN6990795
Kurzübersicht für BRCC3 Antikörper (N-Term) (ABIN6990795)
BRCC36 Antibody is affinity chromatography purified via peptide column.
Immunogen
BRCC36 antibody was raised against a 18 amino acid synthetic peptide from near the amino terminus of human BRCC36. The immunogen is located within amino acids 20 - 70 of BRCC36.
BRCC36 antibody can be used for detection of BRCC36 by Western blot at 0.5 - 2 μ,g/mL. Antibody can also be used for immunohistochemistry starting at 2.5 μ,g/mL. For immunofluorescence start at 20 μ,g/mL.
Antibody validated: Western Blot in human samples, Immunohistochemistry in human samples and Immunofluorescence in human samples. All other applications and species not yet tested.
Beschränkungen
Nur für Forschungszwecke einsetzbar
Format
Liquid
Konzentration
1 mg/mL
Buffer
BRCC36 Antibody is supplied in PBS containing 0.02 % sodium azide.
Konservierungsmittel
Sodium azide
Vorsichtsmaßnahmen
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Lagerung
-20 °C,4 °C
Informationen zur Lagerung
BRCC36 antibody can be stored at 4°C for three months and -20°C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
BRCC36 Antibody: Together with the breast and ovarian predisposition proteins BRCA1 and BRCA2 and RAD51 and BRCC45, BRCC36 forms a holoenzyme complex that possesses a ubiquitin E3 ligase activity. Aberrant levels of BRCC36 were detected in sporadic breast tumors and depletion of either BRCC36 or BRCC45 by siRNA resulted in increased sensitivity to ionizing radiation and defects in the G2/M checkpoint, indicating that BRCC36 acts to enhance cellular survival following DNA damage. Recent experiments have shown that BRCC36 is essential for ionizing radiation-induced BRCA1 phosphorylation and nuclear foci formation, suggesting that BRCC36 may be an important target in the treatment of radiation-resistant breast tumors. At least two isoforms of BRCC36 are known to exist.